COMPANY DESCRIPTION
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs, and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap® mRNA capping technology. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new global headquarters in San Diego, California, to support therapeutic, vaccine, and diagnostic customers.
COMPANY BACKGROUND
Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and a CDMO partner to move mRNA programs from early research to commercial. TriLink’s proprietary CleanCap® co-transcriptional mRNA capping reagent simplifies manufacturing by removing additional enzymatic steps with a high capping efficiency and improved yield over traditional co- transcriptional capping methods.
FACILITIES
TriLink’s custom-built 118,000 sq. ft. facility features over 50,000 sq. ft. of manufacturing space. The facility was designed with flexibility and expansion in mind. Manufacturing space is divided across purpose-built suites, and individual floorplans can be modified to suit program needs. The building’s large footprint and customizable nature enable continued expansion of our capabilities and production scale.
PRODUCTS, SERVICES, CAPABILITIES/MARKETS
TriLink is a pioneer in nucleic acid synthesis and manufacturing since its inception in 1996. With product and service offerings and expertise that have adapted to customer needs over the decades, TriLink remains committed to taking on challenges others simply will not. CDMO services offer a range of mRNA manufacturing grades, from research use only, to customizable intermediate-grade GMPLinkTM, to full GMP-grade with scale-up and technology transfer expertise. TriLink operates a quality system in compliance with ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards. TriLink continues to expand its cGMP and general mRNA, modified nucleoside triphosphate, and oligonucleotide manufacturing capacity at its global headquarters in San Diego, CA, to support therapeutic, vaccine, and diagnostic customers.